Here’s a list of current and soon-to-open clinical trials.  Call us anytime.

Currently Open:

  • Childhood Pulmonary Complications in a Birth Cohort after a Randomized Trial of Antenatal Corticosteroids: the ALPS Follow-Up Study (The ALPS Study)
  • A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol across Sponsors- CFFC-OB-11 (The CFFC study)
  • A Phase 2, Randomized, Parallel-Group, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of CTP-656 with an Open Label Active Comparator in Patients with Cystic Fibrosis with CFTR Gating Mutations (The CONCERT Study)
  • Longitudinal Assessment of Risk Factors for Impact of Pseudomonas aeruginosa Acquisition & Early Anti-Pseudomonal Treatment in Children with Cystic Fibrosis (The EPIC Observational Study)
  • Cystic Fibrosis Patient Registry (The PortCF Registry)
  • Recorded Home Oximetry to Optimize Oxygen Weaning In Premature Infants (The RHO Study)
  • Resistant Airflow Obstruction in Children with Asthma (The ROCAS Study)
  • A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Monotherapy and Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis (The VX-440 Study)
  • Fixed Obstruction in Children with Asthma born Prematurely (The ENO Study)
  • Inhaled Bronchodilator Effect on Respiratory Impedance by FOT in CF and Asthma (The IOS Study)
  • The Effects of Temperature Variation of Liquids on Laryngeal Penetration & Aspiration in Children with Swallowing Dysfunction (The Dysphagia Study)
  • Parental Self-Reported Environmental Exposures in Over 9,000 Children with Respiratory Illness (The Exposure Study)
  • Massively Parallel Sequencing to Identify Microbiological Organisms in Bronchoalveolar Lavage

Fluid in Children, Adolescents and Young Adults Post Hematopoietic Stem Cell Transplant (The

BAL Study)

  • Assessment of the Usefulness of a reformatted Asthma Tool developed by Sesame Street in Communities (The Sesame Study)
  • Multicenter Study Assessing Knowledge, Attitudes, and Practices of People with CF Regarding Safety Monitoring in CF Clinical Trials (The SPARK Study)
  • Standardized Treatment of Pulmonary Exacerbations II (The STOP2 Study)
  • Single Site Prospective Research study testing a Connected Ecosystem of asthma products for children and parents, Protocol: RDD-16127-SPRTE-BM (The SPRTE Study)
  • Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor (TEZ/IVA) in an Orkambi-experienced Population Who Are Homozygous for the F508del-CFTR Mutation (The VX-114 Study)
  • Allergy Evaluations of Children with Persistent Asthma (The A-A QI Study)
  • Ventilation Non-Homogeneity in Children with Scoliosis (The Scoliosis Study)
  • Assessing the Relationship between Eosinophilic Esophagitis and Atopic Disorders in Children (The EOE Study)
  • Assessing the Relationship between the Use of Personal Care Products (PCP) and Asthma (The Care Product Study)
  • Airway microbiome in children with asthma and second hand tobacco smoke exposure (The ETS Microbiome Study)
  • Assessing New Testing Models for Lyme Disease (The Lyme Study)

New Studies Soon to Open:

  • Aztreonam Lysine for Pseudomonas Infection Eradication 2 Study (The ALPINE 2 Study)
  • A Phase 3, Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency (The SIMPLICITY Study)
  • Newborn Screening for Severe Combined Immunodeficiency: Next Generation Sequencing and Long-Term Follow-up (The NBS SCID Study)
  • A Phase 2b, Open-label, Multicenter, Randomized, Active Controlled Trial to Evaluate Fosfomycin/ Tobramycin for Inhalation Solution in Subjects with Cystic Fibrosis and Pseudomonas aeruginosa (The CX-FTI-204 Study)
  • Engineering Evaluation of the Helix Ventilator (The Philips HELIX Study)
  • A Phase Three Study of JBT-101 in Cystic Fibrosis (The CORBUS Phase 3 Study, full title not yet finalized)
  • Nasal Nitric Oxide in Children with Asthma and Secondhand Tobacco Smoke Exposure (The Nasal NO Study)
  • Airway closing index and exercise-induced bronchospasm in children with asthma (The Bronchospasm Study)
  • Defibrotide in Sickle Cell Disease (The Defibrotide Study)
  • A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-440 in Combination With Tezacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F508del/MF) (The VX-440-102 Study)

Studies Closed to Enrollment and Undergoing Data Analysis:

  • Anxiety and COPD Evaluation (The ACE Study)
  • A Phase Two, Double-Blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis, JBT101-CF-001 (The CORBUS Study)
  • Long-Acting Beta Agonist Step Down Study (The LASST Study)
  • Long-Term Administration of Inhaled Mannitol in Cystic Fibrosis- A Safety and Efficacy Trail in Adult CF Subjects, Protocol DPM-CF-303 (The Mannitol Study)
  • The Relationship between Implementation of the 2013 CF Foundation Infection Control Guidelines on the Prevalence and Incidence of Bacterial Respiratory Infections in Patients with Cystic Fibrosis (The CF-QI Study)
  • Evaluation and Management of Cough in Children by Primary Care Pediatricians (The COUGH Study)
  • Effects of Environmental Tobacco Smoke Exposure on Obesity (The ETS-Obesity Study)
  • Prevalence of Atopy in Children with Specific Antibody Deficiency (The Pneumococcal Study)
  • Assessing the Association between EPAs, Competencies, and Milestones in the Pediatric Subspecialties (The EPA Study)
  • Epidemiology of Enterovirus D68: Lower Hudson Valley during the 2014 US National Outbreak and Comparison of Severity of Lower Respiratory Disease in Children Testing Positive for D68 versus Other Viral Pathogens (The EVD68 Study)
  • Improving Specialty Care Follow-up of Children Hospitalized for Asthma
  • Optimizing Treatment for Early Pseudomonas aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo Controlled, Double-Blind, Randomized Trial (The OPTIMIZE-IP-12 Study)
  • A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (The PROSPECT Study)
  • A Phase 2A Randomized, Double-Blind, Placebo-Controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 and Older with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated with Orkambi (The VX-371 Study)
  • Learning from Parental Experiences with Cystic Fibrosis to Improve Services in New York State; Convenience Sample, Multi-Center Study of the Experience of Parents after they are notified about an Abnormal Newborn Screening Test for Cystic Fibrosis (The CF Screen Study)
  • A Phase 3, Randomized, Double-Blind, Placebo Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function (The VX14-661-108 Study)
  • A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-Term Treatment with VX-661 in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation (The VX14-661-110 Study)
  • Resistant Airway Obstruction in Children (The REACH Study)
  • Improving Specialty Care Follow-up of Children Hospitalized for Asthma (The Asthma QI Study)